Caris Life Sciences (CAI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Voting matters and shareholder proposals
Shareholders will vote on the election of ten director nominees at the annual meeting scheduled for June 4, 2026.
Proposal to ratify Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Proxy holders are authorized to vote on any other business that may properly come before the meeting or any adjournment.
Board of directors and corporate governance
Ten individuals have been nominated for election to the board of directors.
Audit committee and external auditor matters
Ratification of Deloitte & Touche LLP as the external auditor for the upcoming fiscal year is up for shareholder approval.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Caris Life Sciences
- Q2 2026 revenue up 45% to $263.7M, margin at 68%, and guidance raised for the year.CAI
Q2 2026 - Rapid growth in precision oncology, AI-driven innovation, and strong financial performance.CAI
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - All board nominees and the auditor were approved; no shareholder questions were received.CAI
AGM 2026 - Rapid growth and innovation in precision oncology, with robust financial and clinical momentum.CAI
Bank of America Global Healthcare Conference 2026 - Q1 2026 revenue up 79% to $216.2M, gross margin 65%, net loss narrowed, strong outlook.CAI
Q1 2026 - Virtual meeting to elect directors and ratify Deloitte as auditor, with strong governance focus.CAI
Proxy filing - Record 2025 revenue and margin gains; 2026 outlook targets $1B+ revenue and continued growth.CAI
Q4 2025 - Record revenue growth, MCED launch, and major partnerships drive transformative expansion.CAI
44th Annual J.P. Morgan Healthcare Conference - IPO targets $364.6M to fund AI-powered oncology solutions; rapid growth, but ongoing losses.CAI
Registration Filing